A nationally coordinated effort in research and development is required to address evidence gaps in the blood sector, and to enable responses to emerging evidence and new technologies.
Under the National Blood Agreement the National Blood Authority (NBA) is charged ‘…to facilitate and fund appropriate research, policy development or other action in relation to new developments by relevant government or non-government persons or bodies.’
Research and Development Strategic Priorities
The NBA has worked with stakeholders to identify the National Blood Research and Development Strategic Priorities 2013-16. The purpose of the publication is to provide a useful resource to guide priority setting for research. It may be used by researchers to support funding requests, including from the National Health and Medical Research Council, by identifying that their research aligns with priorities communicated by governments.
- National Blood Research and Development Strategic Priorities 2013-16 (pdf) (814.78 KB)
- National Blood Research and Development Strategic Priorities 2013-16 (doc) (2.16 MB)
National Blood Sector Research and Development Pilot
In September 2015 the NBA received approval from funding governments to implement a Pilot for funding of research and development activities in the blood sector.
The Pilot will fund a limited number of projects or activities which are assessed as likely to produce valuable research outcomes in identified key priority areas. In addition, information gathered from the Pilot will be used to inform consideration by governments of the viability and potential value of further blood sector specific research and development funding.
The Pilot will be targeted at the following topics, where the priority for research has been identified by pre-existing strategic programs of the NBA and governments in the blood sector:
- patient blood management evidence gaps, as identified in each module of the PBM Guidelines
- efficient and effective use of immunoglobulin products, as highlighted through the Ig Governance Program
The overarching objectives are to identify and support strategic priority areas appropriate for targeted blood sector research funding that will:
- enhance the sustainability and affordability of the national supply of blood products, including through increased efficiency and reduced blood product usage and wastage
- identify appropriate use and reduce inappropriate use of blood products
- maintain or enhance clinical outcomes for patients
by providing evidence or new knowledge to:
- understand the biological action of blood products
- identify optimum treatment, dosing or indications for use for blood products, and
- compare the use of blood products with alternative strategies and treatments.
The Pilot will comprise two funding rounds, commencing from 1 July 2016 and 1 July 2017. A call for proposals for each round will be conducted in early 2016 and 2017, respectively, and funding may be available for up to three years in each round. Projects of various types and duration will potentially be considered in the process.
Applications for grant funding will fall into one of the following categories:
- project grants (up to 3 years)
- seed grants (up to 1 year)
- scholarship grants (up to 1 year)
Round 1- National Blood Sector R&D Pilot
Round 2- National Blood Sector R&D Pilot
Round 2 applications closed 10am, 10 February 2017. The results of the evaluation process will be announced in July 2017.
Frequently asked questions
FAQ's (370.56 KB) (pdf)
FAQ's (781.01 KB) (docx)
More information? Email R&D [at] blood.gov.au If you wish to be notified of R&D pilot grant rounds please subscribe to the NBA’s News feed or register your interest at R&D [at] blood.gov.au.